Yield10 Bioscience, Inc.

Yield10 Bioscience, Inc.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2024, Yield10 Bioscience, Inc. has 642,497.00 shares outstanding.

As of June 30, 2024, Yield10 Bioscience, Inc. maintains a current ratio of 0.16, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2024. Return on assets (ROA) is negative at -287.44, reflecting losses generated across the asset base. The company generates approximately 27,692.31 in revenue per employee across its workforce of 29.25, a quick read on workforce productivity versus industry peers.

As of the close on October 2, 2026, Yield10 Bioscience, Inc.'s stock has declined approximately 99.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.62.

Over the twelve months ended June 30, 2024, Yield10 Bioscience, Inc. generated 810,000.00 in revenue and converted that into -12.70M in net income, yielding earnings per share of -24.97. EBITDA reached -12.32M, while operating income came in at -12.59M.

As of June 30, 2024, Yield10 Bioscience, Inc. holds 733,000.00 in cash and equivalents against 2.79M in total debt, resulting in a net debt position of 263,000.00. Total book value stands at -6.24M, with working capital of -6.46M providing operational flexibility.

Yield10 Bioscience, Inc. produced -5.80M in operating cash flow over the twelve months ended June 30, 2024. After subtracting -19,000.00 in capital expenditures, free cash flow totaled -5.82M - equivalent to -11.44 per share.

These figures cover the twelve months ended June 30, 2024. The operating margin of -1,554.69 and net profit margin of -1,568.15 provide insight into operational efficiency.

Yield10 Bioscience, Inc.'s most recent stock split took place on May 3, 2024 with a 24:1 split ratio.